Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

BACKGROUND: Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multi-refractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. METHODS: We conducted a retrospective review of the outcome of patients with chronic (CP)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Boddu, Prajwal, Shah, Abdul Rashid, Borthakur, Gautam, Verstovsek, Srdan, Garcia-Manero, Guillermo, Daver, Naval, Kadia, Tapan, Ravandi, Farhad, Jain, Nitin, Alhuraiji, Ahmad, Burger, Jan, Kornblau, Steven, Pierce, Sherry, Dellasala, Sara, Jabbour, Elias, Kantarjian, Hagop, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120342/
https://ncbi.nlm.nih.gov/pubmed/28972430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1379076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados